GHRH analog comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Narrated by Fisher Dilke, produced by Nick Catliff, made by Lion Television 10 May A Sense of Disaster, about predicting earthquakes; Allan Lindh of the USGS; 17 October 1989 a large earthquake hit California, killing 67 people, with £7bn of damage in the 1989 Loma Prieta earthquake; Chen Li De of China; China predicted earthquakes by radon gas; Huang Xiang Ning, who predicted an earthquake near Tangshan in late July 1976 - the 1976 Tangshan earthquake occurred on 28 July 1976; the Great Hanshin earthquake on 17 January 1995 in Japan, the worst for seventy years in Japan; nuclear physicist Motoji Ikeya of the University of Osaka; geophysicist Joseph Kirschvink of Caltech, who had worked with bees and electromagnetic fields. Narrated by Barbara Flynn, produced by Bill Jones, directed by Chris Malone, made by Granada Television with the Discovery Channel 17 May Deadly Code, about biological weapons and genetic engineering; Vivienne Nathanson of the BMA; ethnic bioweapons; a religious cult leaves nerve gas on Tokyo underground trains in January 1995; Richard A.
The melting points of branched-chain alkanes can be either higher or lower than those of the corresponding straight-chain alkanes, again depending on these two factors. More symmetric alkanes tend towards higher melting points, due to enthalpic effects when they form ordered crystals, and entropic effects when they form disordered crystals (e.g. neopentane).
== Science and medicine == Anil Kohli, Indian dental surgeon and former president of the Dental Council of India. Martin Kohli (born 1942), Swiss sociologist Prerna Kohli (born 1965), Indian clinical psychologist Pushmeet Kohli, American computer scientist at Google DeepMind where he heads the "Robust and Reliable AI" and "AI for Science" teams. Sanjai Kohli, Indian electrical engineer known for his work in developing GPS Seetu Kohli, Indian architect and interior designer Sunita Kohli (born 1946), Indian architect
Sources: en.wikipedia.org
=== DESI imaging === Desorption electrospray Ionization is a less destructive technique, which couples simplicity and rapid analysis of the sample. The sample is sprayed with an electrically charged solvent mist at an angle that causes the ionization and desorption of various molecular species. Then, two-dimensional maps of the abundance of the selected ions in the surface of the sample in relation with the spatial distribution are generated. This technique is applicable to solid, liquid, frozen and gaseous samples. Moreover, DESI allows analyzing a wide range of organic and biological compounds, as animal and plant tissues and cell culture samples, without complex sample preparation Although, this technique has the poorest resolution among other, it can create high-quality image from a large area scan, as a whole body section scanning. Nano-DESI imaging Nanospray Desoprtion Electrospray Ionization is a minimally destructive soft ionization technique based on liquid extraction. The basic setup consists of two fused silica capillaries (primary and secondary). An extraction solvent is supplied through a primary capillary, forming a liquid bridge at the interface of the two capillaries and extracting molecules from the tissue surface. Afterwards, the extracted analytes are transferred and nebulized through the secondary capillary inside the inlet of a mass spectrometer. Nano-DESI offers great solvent versatility and the possibility of analyte quantification by introducing of internal standards directly into the solvent.
== Awards and honors == Sheiner received the Oscar B. Hunter Award, the highest honor of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), in 2004. He was given an Honorary Doctorate from Uppsala University, Sweden in 1995 and received the Rawls Palmer Progress in Medicine Award of the ASCPT in 1989. Posthumously, several awards have been named in Sheiner's honor, including the International Society of Pharmacometrics (ISoP) Lewis B. Sheiner Lecturer Award and the ASCPT's Sheiner-Beal Pharmacometrics Award.
Hemoglobin concentration measurement is among the most commonly performed blood tests, usually as part of a complete blood count. For example, it is typically tested before or after blood donation. Results are reported in g/L, g/dL or mol/L. 1 g/dL equals about 0.6206 mmol/L, although the latter units are not used as often due to uncertainty regarding the polymeric state of the molecule. This conversion factor, using the single globin unit molecular weight of 16,000 Da, is more common for hemoglobin concentration in blood. For MCHC (mean corpuscular hemoglobin concentration) the conversion factor 0.155, which uses the tetramer weight of 64,500 Da, is more common. Normal levels are:
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\frac {\mathrm {d} N_{A}}{\mathrm {d} t}}&=-\left({\frac {\mathrm {d} N_{B}}{\mathrm {d} t}}+{\frac {\mathrm {d} N_{C}}{\mathrm {d} t}}\right)\\-\lambda N_{A}&=-N_{A}\left(\lambda _{B}+\lambda _{C}\right)\\\end{aligned}}}
The importance of membrane technology is growing in the field of environmental protection (Nano-Mem-Pro IPPC Database). Even in modern energy recovery techniques, membranes are increasingly used, for example in fuel cells and in osmotic power plants.
Tom Kempinski, playwright and screenwriter Peter Kosminsky (born 21 April 1956); writer, playwright, scriptwriter and screenwriter director and producer; has directed Hollywood movies White Oleander and television films, Warriors, The Government Inspector, The Promise, Wolf Hall and The State; born in London in 1956 to Jewish parents. Hyam Maccoby (Hebrew: חיים מכובי, 1924–2004) was a Jewish-British scholar, dramatist, playwright and author of over fifteen scholarly books, specialising in the study of the Jewish and Christian religious traditions. He was known for his theories of the historical Jesus and the origins of Christianity. Maccoby's play The Disputation has been widely performed, and was broadcast by Channel 4 starring Christopher Lee and Toyah Willcox. Hyam Maccoby's daughter is the anti-Zionist BDS activist, organiser of Jews for Justice for Palestinians and author, Deborah Maccoby, acknowledged for her monograph on Isaac Rosenberg. Patrick Marber, playwright and comedian Laurence Marks (British writer) (born 8 December 1948), producer, scriptwriter, screenwriter and one half of writing duo Marks and Gran (with Maurice Gran). Harold Pinter, Nobel prize-winning playwright; Pinter signed the mission statement of Jews for Justice for Palestinians in 2005 and its full-page advertisement, "What Is Israel Doing? A Call by Jews in Britain", published in The Times on 6 July 2006, and he was a patron of the Palestine Festival of Literature. In April 2008, Pinter signed the statement "We're not celebrating Israel's anniversary".
== History == The application for imipenem/cilastatin/relebactam was granted Qualified Infectious Disease Product (QIDP), fast track, and priority review designations by the U.S. Food and Drug Administration (FDA). The FDA granted the approval of Recarbrio to Merck & Co., Inc. The determination of efficacy of imipenem/cilastatin/relebactam was supported in part by the findings of the efficacy and safety of imipenem-cilastatin for the treatment of complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). The contribution of relebactam to imipenem/cilastatin/relebactam was assessed based on data from in vitro studies and animal models of infection. The safety of imipenem/cilastatin/relebactam, administered via injection, was studied in two trials (Trial 1/NCT01505634, Trial 2/NCT01506271), one each for cUTI and cIAI. The cUTI trial included 298 adult participants with 99 treated with the proposed dose of imipenem/cilastatin/relebactam. The cIAI trial included 347 participants with 117 treated with the proposed dose of imipenem/cilastatin/relebactam. Trial 1 enrolled adult participants hospitalized with cUTI. Trial 2 enrolled adult participants hospitalized with cIAI that required surgery or drainage. In both trials, participants were assigned to either imipenem/cilastatin with varying doses of relebactam or imipenem/cilastatin with placebo intravenously, every 6 hours for 4 to 14 days. Neither the participants nor the investigators knew which treatment was being given until after the trial was completed.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.